Bio-Techne Beats Estimates, But Acquisition Looms Over Stock Performance

Bio-Techne reported its Q4 revenues at $321.2 million, exceeding estimates but showing mixed financial results. The company's adjusted earnings per share (EPS) fell 1.9% year-over-year to $0.52.

The strong organic growth of 8% in the Diagnostics and Spatial Biology segments was unable to move the stock significantly due to the pending acquisition offer from Merck KGaA at $73 per share.

Benchmark maintains a 'Hold' rating, indicating stable stock performance until the deal concludes. The company's stock remains close to the acquisition offer price.